IOL Chemicals and Pharmaceuticals Ltd - Q2 FY 20 RESULTS - REVIEW

IOL Chemicals and Pharmaceuticals Ltd

Q2 FY 20 RESULTS - REVIEW

About IOL Chemicals and Pharmaceuticals Limited (IOLCP)

Company was established in 1986 is one of the leading Active Pharmaceutical ingredients/ bulk drugs manufacturing Company and is a significant player in the specialty chemicals space with world class facilities. 

IOLCP  has wide presence across  major therapeutic categories  like,  Pain Management, anti-convulsants, anti-diabetes, anti- cholesterol and anti-platelets. 

IOLCP's  product  portfolio  includes  Active Pharmaceutical lngredients;   Ibuprofen,   Metformin,   Fenofibrate, Clopidogrel,  Lamotrigine,  Pantoprazole  and  specialty  chemicals  such  as  Ethyl Acetate,  lso Butyl Benzene, Mono Chiaro Acetic Acid and Acetyl Chloride. 

Company is World's largest producer of the Ibuprofen with an installed capacity of 12,000 TPA and  having backward  integrated manufacturing facility.  

The Company has DSIR approved R&D which is fully equipped to validate existing processes. 

The Central  and  State  Government approved  Effluent Treatment Plant (ETP)  had been  set up  with  zero  effluent discharge  system  along with  17  MW  captive  Co- Generation plant for self reliance. 

IOLCP's overseas customers are spread out across several  countries including UK, Austria, Belgium,  Hungry,  Spain, Germany,  Italy, Netherlands,  Switzerland, Portugal, Poland,  Ireland,  USA,  Australia,  Chile,  Peru,  Brazil,  Argentina,  Colombia,  Mexico, Indonesia,  South  Korea,  Thailand  etc.  

Products  are  sold  primarily  to  Branded Generic formulators both in India & Overseas

IOL has posted remarkable operational and financial performance for the second quarter of financial year 2019-20. It was after a consistent first quarter performance.

Quarter ended September 2019 vis a vis Quarter ended September 2018 

• Income from operations increased by 5 % to~Rs.452 crore from Rs.429 crore.

• EBIDTA increased by 68 % to~Rs.136 crore from Rs.81 crore.

• Net Profit increased by 132 % to~Rs.88 crore from Rs.38 crore.

• EPS increased by 125 % to Rs.15.42 from Rs.6.84.

Half year ended September 2019 vis a vis Half year ended September 2018 

• Income from operations increased by 19 % to~ 948 crore from Rs.794 crore.

• EBIDTA increased by 129 % to Rs.284 crore from Rs.124 crore.

• Net Profit increased by 226 % to Rs.173 crore from Rs.53 crore.

• EPS increased by 224 % to Rs.30.42 from Rs.9.40. 

Mr Vijay Garg, Joint Managing Director said :

"We are very delighted to announce consistently strong operational and financial performance during the 2ndquarter of the Financial Year 2019-20. 

We have successfully set up Unit VI to manufacture Pantoprazole with a capacity of 240 MT per annum which will enable to increase the revenue of the Company. 

He further added, we have made the pre-payment of term loan of aggregate amount of Rs.161.44 crore till date to reduce the financial cost of the Company."